Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib added to pertuzumab and trastuzumab after local treatment of isolated brain progression in HER2-positive metastatic breast cancer
2020-005735-79Phase 2Active
- Sponsor
- Unicancer
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib, pertuzumab and trastuzumab in breast cancer, sponsored by Unicancer. Primary endpoint: 6-month progression-free survival rate. Started Jun 2021; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-005735-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005735-79.